Psoriasis and serum lipid abnormalities

Dermatologic Therapy

Volumn 23, Issue 2, 2010, Pages 160-173

  Pietrzak, Aldona ^a   Chodorowska, Grazyna ^a   Szepietowski, Jacek ^b   Zalewska Janowska, Anna ^c   Krasowska, Dorota ^a   Hercogová, Jana ^d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL; CYCLOSPORIN; FISH OIL; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; PHOSPHATIDYLCHOLINE; SYNAPSIN I; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; DERMATITIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ECZEMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PSORIASIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEINS; DIETARY FATS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PSORIASIS; YOUNG ADULT;

EID: 77950118835     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01311.x     Document Type: Review

References (72)

1. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult - onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009 : 60 (3 394 401.
2. Romanowska M, Yacoub N, Seidel H, et al. PPAR delta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 2007 : 128 (1 110 124.
3. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009 : 60 (2 225 230.
4. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009 129 (7 1601 1603.
5. Pietrzak A, Janowski K, Łopatynski J, et al. Psoriasis and heart. Something new under the sun. Gital Dermatol Venereol 2006 : 141 : 457 463.
6. Pietrzak A, Lecewicz-Torurn B, Ködziela-Wypyska G. Changes in the digestive system in patients suffering from psoriasis. Ann Univ Marie Curie Sklodowska [Med] 1998 : 53 : 187 194.
7. Pietrzak A, Toruniowa B, Pietrzak B, Chwaluk J. Profil lipidowy chorych na łuszczyç w zalezności od płci i wieku. Przegl Dermatol 1994 : 81 (5 441 449.
8. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005 : 438 : 612 621.
9. Orfanos CE. Scanning electron microscopy in psoriasis. In : Farber EM, Cox AJ, Jacobs PH, eds. Psoriasis. Proceedings of the International Symposium. Stanford, CA : Stanford University Press, 1971 : 169 185.
10. Chibowska M. Role of serum lipids in psoriasis. Przegl Dermatol 1970 : 57 (2 255 260.
11. Pietrzak A, Jastrzebska I, Krasowska D et al. Serum pancreatic lipase [EC 3.1.1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Mol Catal B Enzym 2006 : 40 : 144 154.
12. Wilkinson DI. Lipid metabolism in psoriasis. In : Farber EM, Cox AJ, Jacobs PH, eds. Psoriasis. Proceedings of the International Symposium. Stanford, CA : Stanford University Press, 1971 : 277 287.
13. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 : 54 : 614 621.
14. Ishikawa H, Sato H. Demonstration of beta-lipoproteins in the psoriatic skin by immunofluorescent technique. Arch Dermatol Forsch 1974 : 30 (8 191 206.
15. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low - density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007 : 2007 : ID 78454, 5 pages.
16. Pietrzak A, Ködzielewski J, Janowski K, et al. Lipoproteid (a) in patients with psoriasis: association with lipid profiles and disease severity. Int J Dermatol 2009 : 48 : 379 387.
17. Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. JEADV 2007 : 21 : 802 805.
18. Gisondi P, Tessari G, Conti A, Kane D, Lowe G, McInnes IB. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 : 157 : 68 73.
19. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology 2008 : 216 : 152 155.
20. Tam LS, Tomlinson B, Chu TTW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology 2008 : 47 : 718 723.
21. Yalcin H, Balci DD, Ucar E, et al. Myocardial perfusion is preserved in patients with psoriasis without clinically evident cardiovascular disease. JEADV 2009 : 23 : 798 802.
22. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009 : 160 : 1048 1056.
23. Feretti G, Simonetti O, Offidani AM, et al. Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children. Pediatr Res 1993 : 33 (5 506 509.
24. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001 : 303 : 33 39.
25. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007 : 21 : 1330 1332.
26. Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol 2007 : 52 : 89 92.
27. Tarek A., El Saied, Said Hammad Abdou. Atherosclerotic Risk in Psoriasis. Journal of PALD 2005 : 16 (2 39 45.
28. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphines are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006 : 154 (2 345 352.
29. Bajaj BR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis representing at Liaquat University Hospital Hyderabad. J Pak Med Assoc 2009 : 59 : 512 515.
30. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008 : 159 : 956 960.
31. Gelfand JM, Neimann AL, Shin DB, Wang X, Margollis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 : 296 : 1735 1741.
32. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009 : 218 (2 110 113.
33. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 : 141 : 1527 1534.
34. Huerta C, Rivero E, Garcia Rodrigues L.A. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007 : 143 (12 1559 1565.
35. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008 : 159 : 895 902.
36. Ludwig RJ, Herzog C, Rostock A. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 : 156 : 271 276.
37. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 : 55 : 829 835.
38. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, Bustos-Saldana R, Gonalez-Ortiz M. Lipid profile, insulin secretion and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003 : 48 : 882 885.
39. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007 : 167 (15 1670 1675.
40. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007 : 56 : 629 634.
41. Sommer DM, Jenish S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 : 298 : 321 328.
42. Toker A, Kadi M, Yildirim AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009 : 27 : 176 180.
43. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. JDD 2008 : 7 (4 373 377.
44. Masterolonardo M, Picardi A, Alicino D, Bellomo A, Pasquini P. Cardiovascular reactivity to experimental stress in psoriasis: a controlled investigation. Acta Derm Venereol 2006 : 86 (4 340 344.
45. Pietrzak A, Borowik M, Chodorowska G, et al. Profil lipidowy oraz surowiczy poziom NT - proBNP a adaptacja do choroby u pacjentów z łuszczycö. In : Janowski K, Gierus J. eds. Człowiek chory aspekty biopsychospołeczne. Lublin : Wydawnictwo Drukarnia Best Print s.c., 2009 : 348 360.
46. Walldius G, Jungner I. The ApoB/ApoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006 : 259 : 493 519.
47. Leren TP, Maartmann-Moe K, Thune P, Berg K. Low density lipoprotein receptors in cultured skin fibroblasts from psoriasis patients. Clin Genet 1984 : 25 : 230 241.
48. Ručević I, Perl A, Barišić-Druško V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol Suppl 2003 : 27 (1 41 48.
49. Naldi L, Chatenoud L, Belloni A, et al. Medical history, drug exposure and risk of psoriasis. Evidence from an Italian case-control study. Dermatology 2008 : 216 (2 125 130.
50. Edwards BD, Bhatnagar D, Mackness MI, et al. Effect of low-dose cyclosporine on plasma lipoproteins and markers of cholestasis in patients with psoriasis. QJM 1995 : 88 (2 109 113.
51. Lassus A, Dahlgren AL, Halpern MJ, Santalahti J, Happonen HP. Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis. J Int Med Res 1990 : 18 (1 68 73.
52. Meffert H, Bräutigam M, Färber L, Weidinger G. Low-dose (1.25 mg/kg) cyclosporine A: treatment of psoriasis and investigation of the influence of lipid profile. Acta Derm Venereol 1997 : 77 (2 137 141.
53. Miquel J, Bernd A, Semere JM, Diaz-Alperi J, Ramirez A. The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 2002 : 34 (1 37 46.
54. Osmancevic A, Nilsen LT, CWilhelmsen K, et al. Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. J Eur Acad Dermatol Venerol 2009 : 23 (10 1133 1140.
55. Reiss F, Jaimovich L. The influence of sitosterol upon psoriasis vulgaris; observations on electrophoretic pattern. Dermatologica 1958 : 117 (5 393 401.
56. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007 : 3 : 831 839.
57. Vallesi G, Raggi F, Fufini S, Gizzi S, Ercolani E, Rossi R. Effects of cyclotronic ion resonance on human metabolic processes: a clinical trial and one case report. Electromagn Biol Med 2007 : 26 (4 283 288.
58. Shrinsky IV, Shrinskt VS. Efficacy of simvastin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007 : 57 (3 529 531.
59. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006 : 154 (1 83 86.
60. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989 : 20 (6 1088 1093.
61. Vahlquist A, Törmä H. Retinoids and keratinisation: current concepts. Int J Dermatol 1988 : 27 : 81 95.
62. Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ. Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate. Arch Dermatol 1987 : 123 (4 471 475.
63. Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB. Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. J Am Acad Dermatol 1988 : 19 (1 Pt 1 76 82.
64. Marsden JR. Effect of dietary fish oil on hyperlipidaemia due to isotretinoin and etretinate. Hum Toxicol 1987 : 6 (3 219 222.
65. Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991 : 25 (4 648 651.
66. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002 : 114 (23-24 1004 1007.
67. Antoniou C, Dessinoti C, Katsambas A, Stratigos AJ. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-α therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 2007 : 156 : 1090 1092.
68. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006 : 33 (12 2440 2446.
69. Ohtsuka T. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. J Arch Dermatol Res 2008 : 300 (10 545 550.
70. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007 : 20 (4 731 736.
71. Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol 2003 : 149 : 1305.
72. Oliviero F, Sfriso P, Baldo G, et al. Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol 2009 : 27 (1 79 83.